Rituximab has recently been added to the arsenal of treatments for lymphoma patients. Adding rituximab to traditional chemotherapy regimens has been found to increase an individual’s chance of cure and extend their survival time. Results from British Columbia indicate that rituximab is also a cost-effective treatment, providing good value for money.
Traditionally, economic evaluations of rituximab [...]
New Therapies Can Turn Cancer Into Chronic Disease (Also Included In: Lymphoma / Leukemia / Myeloma).
Article by medicalnewstoday.com on May 24, 2010
Two new studies suggest that the prolonged use of cancer drugs helped stunt the progress of the disease, a shift from the scheduled courses of treatment typically delivered to patients, The Wall Street [...]
Johns Hopkins Kimmel Cancer Center researchers say preliminary studies show that a vaccine made with leukemia cells may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Imatinib mesylate (Gleevec).
Gleevec, one of the first targeted cancer therapies with wide success in CML patients, [...]
Researchers from the Sackler Center at Weill Cornell Medical College have designed a new class of drugs that targets BCL6, a master regulatory protein responsible for causing the most common type of non-Hodgkin’s lymphoma.
Findings published in today’s issue of Cancer Cell show that an experimental compound designed by a team of researchers from Weill Cornell [...]
A personalized vaccine for lymphoma, BiovaxID (developed by Biovest International), has been granted orphan drug status by the US Food and Drug Administration, which will grant it a 7-year period of market exclusivity after approval. It is one of a few late-stage patient-specific cancer vaccines vying to be the first to reach the market, according [...]